Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
humanized monoclonal antibody for the treatment ofcolorectal cancer .
Etymologies
from Wiktionary, Creative Commons Attribution/Share-Alike License
Support
Help support Wordnik (and make this page ad-free) by adopting the word labetuzumab.
Examples
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.
-
In a mouse model of human pancreatic cancer, SN-38 conjugates of labetuzumab and hRS7 produced enhanced antitumor effects versus veltuzumab-SN-38 conjugate, which does not target pancreatic cancer, suggesting the binding abilities of labetuzumab and hRS7 were retained in both conjugates.
-
The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.
-
The first study reported at the AACR conference evaluated 4 linkers to connect SN-38 to labetuzumab or hRS7, two of the Company's proprietary humanized monoclonal antibodies.
-
(Nasdaq: IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that results presented at the 2009 Gastrointestinal Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, selectively delivers SN-38 to human colon carcinoma in animal models as an effective new therapy.
-
In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer.
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.